Dasatinib

(Sprycel)

Dasatinib

Drug updated on 9/14/2023

Dosage FormTablet (oral; 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg)
Drug ClassKinase inhibitor
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
  • For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
  • For adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
  • For the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase.
  • For the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.